TF Regimen And FOLFOX6 Regimen On Advanced Gastric Carcinoma In Advanced Gastric Cancer

Objective:To compare the efficacy and toxicity of TF regimen and FOLFOX6 regimen on advanced gastric carcinoma (AGG) in gastric cancer. Methods:Retrospective analysis of 54 cases confirmed by pathology in patients with advanced gastric cancer,28 patients in group A treated with DF regimen:Docetaxel 50mg/m2,d1;CF400mg/m2,d1;5-FU400mg/ m2,d1;5-FU2400-3000mg/m2,CⅣV(46h), were given, repeated every 14 days; 26 patients in group B treated with FOLFOX6 regimen:L-OHP100 mg/m2,d1;CF400mg/m2,d1; 5-FU400mg/m2,d1;5-FU2400-3000mg/m2,CⅣ(46h), were given, repeated every 14 days.The efficacy,Progression Free Survival(PFS),overall survival (OS) improvement of QOL and toxicity of the two regimens were analyzed. Results:The response rate (RR) of group A and B were 46.40%and 46.20%,Difference was statistically significant(p=0.99). The median PFS was 5.50months in group A and5.50months in group B(P=0.54).The median survival time was 8.00 months in group A and 8.50 months in group B,Difference was statistically significant(p=0.71).The improvement rate of QOL of A and B were 64.30%and 30.80%,Difference was statistically significant(P= 0.04). Major side effect of the two groups had significant deference (P<0.05). Conclusion:Both TF and FOLFOX6 regimens were effective in treating advanced gastric cancer in patients. TF regimen is better than FOLFOX6 regimen on the improvement of QOL and toxicities survivability.